Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Ligand Pharmaceuticals Incorporated (LGND) - free report >>
Emergent Biosolutions Inc. (EBS) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ligand Pharmaceuticals Incorporated (LGND) - free report >>
Emergent Biosolutions Inc. (EBS) - free report >>
Image: Bigstock
Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology
Ligand Pharmaceuticals Incorporated (LGND - Free Report) announced that it has entered into a worldwide license agreement with California-based TeneoBio, Inc. Under the deal, TeneoBio will utilize OmniFlic technology from Ligand’s OmniAb platform for the discovery of fully human bispecific antibodies for developing treatments targeting various diseases, with initial focus on cancer, autoimmunity and infectious diseases.
This deal will see Ligand receiving annual platform access payments, milestone payments, sublicensing fees and royalties for products developed by incorporating an OmniFlic antibody. Meanwhile, TeneoBio will be responsible for all costs related to the programs.
We remind investors that OmniAb, an antibody-generating platform, became part of Ligand’s technology portfolio following the Jan 2016 acquisition of OMT, Inc., a privately held company focused on genetic engineering of animals for the generation of human therapeutic antibodies. The acquisition not only diversified Ligand's business by adding OmniAb to its technology portfolio, which had already consisted of the Captisol formulation technology, but also created a strong platform to aid the company’s search for new licenses and partnerships.
Note that OmniAb includes three transgenic animal platforms – OmniRat, OmniMouse and OmniFlic – for producing mono- and bispecific human therapeutic antibodies.
Ligand has struck quite a few partnerships with other health care companies for its OmniAb platform. This January, the company signed a worldwide licensing agreement with Emergent BioSolutions, Inc. (EBS - Free Report) .
Such deals are important for Ligand as they provide the company with funds in the form of milestones, royalty and other payments, thereby boosting its top line.
LIGAND PHARMA-B Price
LIGAND PHARMA-B Price | LIGAND PHARMA-B Quote
Zacks Rank & Key Picks
Ligand currently sports a Zacks Rank #1 (Strong Buy). Other equally ranked stocks in health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Anika Therapeutics Inc. (ANIK - Free Report) . You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>